Literature DB >> 28677013

A meta-analysis survey of appropriate bone turnover markers in the detection of bone metastasis in lung cancer.

Jianda Huang1, Tongjie Gu2, Jun Ying2.   

Abstract

BACKGROUND: A number of studies have investigated the clinical significance of bone turnover markers (BTMs) for the diagnosis of bone metastasis (BM) in lung cancer; however, they led to contradictory results. The aim of this meta-analysis was to investigate whether BTMs differ between lung cancer patients with and without BM.
METHODS: Articles were identified by searching Medline, Embase, Web of Science and Scopus. The studies that were identified were pooled and the weighted mean difference (WMD) and its corresponding 95% confidence interval (CI) were calculated. Subgroup analyses and publication bias detection were also conducted.
RESULTS: A final analysis of 1720 subjects (707 patients with BM and 1013 patients without BM) was performed from 16 cohort studies. From the pooled data in the meta-analysis, the total alkaline phosphatase (TALP) (104.35 U/l [95% CI 33.36-175.34]), bone-specific ALP (BALP) (13.24 μg/l [95% CI 8.50-17.98] or 6.84 U/l [95% CI 2.98-10.70]), C-terminal cross-linked telopeptide of type I collagen (ICTP) (5.07 μg/l [95% CI 3.58-6.56]) and N-terminal cross-linked telopeptide of type I collagen (NTX) (5.08 nM bone collagen equivalent/l [95% CI 2.82-7.33]) were significantly lower among BM patients than non-BM patients. Subgroup analyses detected that the serum level of tartrate-resistant acid phosphatase isoform 5b was significantly reduced in Caucasian patients with BM (-0.64 U/l [95% CI -1.02 to -0.25]), while increased in Asian patients with BM (2.69 U/l [95% CI 0.08-5.31]), compared to patients without BM.
CONCLUSIONS: The present meta-analysis suggested that serum measurement of TALP, BALP, ICTP and NTX might be helpful in detecting BM in lung cancer.

Entities:  

Keywords:  Bone metastasis; Bone turnover markers; Lung cancer; Meta-analysis

Mesh:

Substances:

Year:  2017        PMID: 28677013     DOI: 10.1007/s10147-017-1159-1

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  40 in total

1.  Serum tartrate resistant acid phosphatase as a potential marker of bone metastasis from breast cancer.

Authors:  N Wada; S Ishii; T Ikeda; K Enomoto; M Kitajima
Journal:  Anticancer Res       Date:  1999 Sep-Oct       Impact factor: 2.480

Review 2.  Metastasis to bone: causes, consequences and therapeutic opportunities.

Authors:  Gregory R Mundy
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

Review 3.  The prognostic role of bone turnover markers in multiple myeloma patients: The impact of their assay. A systematic review and meta-analysis.

Authors:  Valentina Pecoraro; Laura Roli; Luca Germagnoli; Giuseppe Banfi
Journal:  Crit Rev Oncol Hematol       Date:  2015-05-21       Impact factor: 6.312

4.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

Review 5.  Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data.

Authors:  Giannis Mountzios; Vassilis Ramfidis; Evangelos Terpos; Kostantinos N Syrigos
Journal:  Clin Lung Cancer       Date:  2011-05-17       Impact factor: 4.785

Review 6.  Mechanisms of cancer metastasis to the bone.

Authors:  Juan Juan Yin; Claire B Pollock; Kathleen Kelly
Journal:  Cell Res       Date:  2005-01       Impact factor: 25.617

7.  The clinical importance of bone metabolic markers in detecting bone metastasis of lung cancer.

Authors:  Suna Bilgin Bayrak; Emel Ceylan; Mukadder Serter; Fisun Karadağ; Ece Demir; Orhan Çildağ
Journal:  Int J Clin Oncol       Date:  2011-06-21       Impact factor: 3.402

8.  Usefulness of bone markers for detection of bone metastases in lung cancer patients.

Authors:  Füsun Alataş; Ozkan Alataş; Muzaffer Metintaş; Omer Colak; Sinan Erginel; Emel Harmanci
Journal:  Clin Biochem       Date:  2002-06       Impact factor: 3.281

Review 9.  Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.

Authors:  Robert Coleman; Janet Brown; Evangelos Terpos; Allan Lipton; Matthew R Smith; Richard Cook; Pierre Major
Journal:  Cancer Treat Rev       Date:  2008-06-24       Impact factor: 12.111

10.  The role of whole-body FDG PET/CT, Tc 99m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer.

Authors:  Joo-Won Min; Sang-Won Um; Jae-Jun Yim; Chul-Gyu Yoo; Sung Koo Han; Young-Soo Shim; Young Whan Kim
Journal:  J Korean Med Sci       Date:  2009-04-21       Impact factor: 2.153

View more
  3 in total

Review 1.  [Progress of Biomarkers in Diagnosis of Bone Metastases of Lung Cancer].

Authors:  Chao Meng; Chuanhao Tang; Jun Liang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-08-20

2.  Circulating liver enzymes and risks of chronic diseases and mortality in the prospective EPIC-Heidelberg case-cohort study.

Authors:  Verena Katzke; Theron Johnson; Disorn Sookthai; Anika Hüsing; Tilman Kühn; Rudolf Kaaks
Journal:  BMJ Open       Date:  2020-03-08       Impact factor: 2.692

3.  Risk factors for bone metastasis from renal cell cancer.

Authors:  Xuan-Yin Chen; Min Lan; Yang Zhou; Wen-Zhao Chen; Dong Hu; Jia-Ming Liu; Shan-Hu Huang; Zhi-Li Liu; Zhi-Hong Zhang
Journal:  J Bone Oncol       Date:  2017-11-02       Impact factor: 4.072

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.